Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-60,204
Closed -$2.23M 594
2022
Q1
$2.23M Hold
60,204
0.01% 248
2021
Q4
$2.74M Hold
60,204
0.01% 228
2021
Q3
$3.81M Hold
60,204
0.01% 211
2021
Q2
$5.51M Sell
60,204
-6,311
-9% -$502K 0.02% 191
2021
Q1
$4.53M Sell
66,515
-11,785
-15% -$915K 0.02% 196
2020
Q4
$5.67M Buy
78,300
+370
+0.5% +$21.4K 0.02% 178
2020
Q3
$2.96M Buy
77,930
+439
+0.6% +$14.8K 0.01% 197
2020
Q2
$2.75M Buy
77,491
+3,170
+4% +$90.2K 0.01% 203
2020
Q1
$1.62M Buy
74,321
+15,251
+26% +$342K 0.01% 214
2019
Q4
$1.27M Sell
59,070
-9,926
-14% -$228K 0.01% 250
2019
Q3
$1.56M Buy
68,996
+312
+0.5% +$8.64K 0.01% 233
2019
Q2
$2.47M Buy
+68,684
New +$2.2M 0.01% 202
2019
Q1
Sell
-10,000
Closed -$251K 334
2018
Q4
$251K Buy
+10,000
New +$257K ﹤0.01% 330

Other funds holding CDNA

TIAA FSB's CDNA Position: Q2 2022 in Review

TIAA FSB sold out of CareDx (CDNA) in Q2 2022, closing a stake of 60,204 shares — an estimated $2.23M sold.

TIAA FSB first reported a position in CDNA in Q4 2018 and held it in 13 quarters. The position peaked at $5.67M in Q4 2020. 184 funds tracked by Wall St. Rank hold CDNA as of Q2 2022.

  • TIAA FSB reported no remaining CareDx position as of Q2 2022 after selling out during the quarter.
  • TIAA FSB sold 60,204 CareDx shares in Q2 2022, an estimated $2.23M.
  • TIAA FSB first reported a position in CareDx in Q4 2018 and held it in 13 quarters.
  • TIAA FSB's CareDx position peaked at $5.67M in Q4 2020.
  • 184 funds tracked by Wall St. Rank held CareDx as of Q2 2022.

Based on TIAA FSB's 13F filing for Q2 2022, filed 9 Aug 2022.